New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - letermovir 240mg - film coated tablet - 240 mg - active: letermovir 240mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry yellow 39k120004 povidone as povidone 25 purified water - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - letermovir 480mg - film coated tablet - 480 mg - active: letermovir 480mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry pink 39k140009 povidone as povidone 25 purified water - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - letermovir, quantity: 480 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydroxypropylbetadex - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - letermovir, quantity: 240 mg - injection, concentrated - excipient ingredients: water for injections; hydroxypropylbetadex; sodium chloride; sodium hydroxide - prevymis is indicated for the prophylaxis of cytomegalovirus (cmv) infection or disease in adult cmv-seropositive recipients [r+] of an allogeneic hematopoietic stem cell transplant (hsct).

European Union - English - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials for systemic use, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Canada - English - Health Canada

bgp pharma ulc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

bgp pharma ulc - valproic acid (divalproex sodium) - tablet (delayed-release) - 125mg - valproic acid (divalproex sodium) 125mg - miscellaneous anticonvulsants

Canada - English - Health Canada

bgp pharma ulc - valproic acid (divalproex sodium) - tablet (delayed-release) - 250mg - valproic acid (divalproex sodium) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

bgp pharma ulc - valproic acid (divalproex sodium) - tablet (delayed-release) - 500mg - valproic acid (divalproex sodium) 500mg - miscellaneous anticonvulsants

Canada - English - Health Canada

teva canada limited - valproic acid - capsule - 250mg - valproic acid 250mg - miscellaneous anticonvulsants